论文部分内容阅读
新近在一个肺癌亚型中发现的ROS1融合基因已受到临床关注,因为据报道ROS1融合基因阳性肺癌对激酶抑制剂敏感。为了更好地认识这些肿瘤,该作者用反转录聚合酶链技术检查了799例手术切除的非小细胞肺癌,发现15例携有ROS1融合基因转录子(占肺癌的2.5%)。与ROS1发生融合的最常见基因是CD74,其次是EZR。这些受累的患者往往是非吸烟的年轻女性,其总体生存率与ROS1融合基因阴性的患者相似。除1例为腺鳞癌外,其余ROS1融合基因阳性的患者均为腺
The ROS1 fusion gene, recently found in one lung cancer subtype, has gained clinical interest because it is reported that ROS1 fusion gene-positive lung cancer is sensitive to kinase inhibitors. To better understand these tumors, the authors examined 799 surgically resected non-small cell lung cancers using reverse transcriptase-polymerase chain reaction and found that 15 had ROS1 fusion transcripts (2.5% of lung cancers). The most common gene that is fused to ROS1 is CD74, followed by EZR. These affected patients are often non-smoking young women with overall survival rates similar to those with negative ROS1 fusion genes. In addition to one case of adenosquamous carcinoma, the rest of the ROS1 fusion gene-positive patients were glandular